At four years after the Symposium on the 'Recent advances in adipose tissue biology', also organized in Quebec City by the DB Brown Research Chair on Obesity, we are now confronted with the fact that far more complex roles can be assigned to adipose tissue proteins. An impressive panel of speakers have highlighted the importance of nuclear proteins beyond their established respective function.
Dr Ron Law started the afternoon session on peroxisome proliferator-activated receptors (PPARs) and their novel targets in the vessel wall. Previous work from many groups have already established an important role of PPARg in vessel wall macrophages through its implication in the transcription of genes involved in cholesterol homeostasis, macrophage differentiation, and inflammation. 1 Law provided new data showing that PPARg expressed in vascular smooth muscle cells (VSMC) is upregulated upon wall mechanical damage. His findings suggested that both PPARg ligands and PPARg overexpression inhibit the formation of the neointima by suppressing VSMC proliferation during the G 1 to S phase transition. This suppression was due in part to the hypophosphorylation of Rb, a PPARg corepressor that also inhibits the adipogenic action of the nuclear receptor (which was discussed earlier in the day by Lluis Fajas). PPARg ligands also stimulate VSMC apoptosis through the induction of GADD45, a second nuclear receptor involved in cell survival. Law argued that his findings are consistent with the impact of PPARg ligands such as troglitazone or rosiglitazone on neointimal tissue formation after coronary stent implantation in diabetic patients with macrovascular disease, although the effect of PPARg ligands on VSMC cells per se has not been determined in the clinic. His data added new concepts to the controversial effects of PPARg on angiogenesis, in which VSMC proliferation probably plays an active contribution. The use of PPARg knockin, knockout, and transgenic mice could shed more light on this process. The second talk of the session was presented by Dr Robert Hegele, who found and described new PPARg mutations that have a large impact on fat accumulation and manifestations of the metabolic syndrome. He first confirmed that the largely described and quite frequent Pro12Ala mutation possesses some beneficial impact on BMI and insulin resistance only in a few populations, 2 which points at best to an important gene-environment interaction. Consistent with the known pivotal role of PPARg in adipogenesis, Hegele found a much less frequent loss-of-function PPARg mutation (F388L) for which heterozygous bearers are characterized by a condition of partial lipodystrophy that cannot be explained by more classical nuclear lamin mutations. The consequences of the F388L mutation are much stronger than in PPARg7mice, and the lipodystrophy of the carriers could actually be better compared to the quite marked phenotype of the hypomorphic PPARg mouse. 3 Hegele's several models for monogenic metabolic syndrome could be useful to determine in humans the cause of particular metabolic disorders, and thus Hegele rightly suggested that the etiology of familial partial lipodystrophy (FPLD) should be studied like familial dyslipidemia in order to determine its molecular mechanisms. The second part of the session was aimed at describing new roles of known nuclear proteins in adipose tissue. Dr Domenico Accili elegantly proposed that the FOXO family of transcription factors controls metabolism in several tissues, 4 including the pancreas and the liver, where Foxo1
regulates gluconeogenesis with the help of PGC-1 (addressed earlier in the day by Pere Puigserver). Foxo1 also impacts on adipogenesis in mice 5 and flies, 6 likely during the first phase of clonal expansion during the differentiation process. Foxo1 acts downstream of the insulin signaling cascade, so it is not surprising that in mice, deletions of Foxo1 or the insulin receptor affect metabolism in a convergent molecular pathway and with convergent consequences on insulin sensitivity and adipose tissue development. While his lab showed that Foxo1 can interact with Sirt1, an NAD-dependent nuclear deacetylase, Leonard Guarente rather discussed the new role of Sirt1 in adipocytes. Sirt1 orthologs are known to mediate the life-extending effect of calorie restriction in yeast, and it can also increase lifespan in worms when overexpressed. One of the first events of calorie restriction is a reduction in body fat, and recent studies have shown that a specific decrease in fat stores results in an increased lifespan. 7, 8 Guarente described that in fat cells, Sirt1 stimulates lipolysis and prevents adipogenesis by inhibiting the transcriptional activity of PPARg through the PPARg corepressors NCoR and SMRT. 9 Most interestingly, Sirt1 appears to be activated in most mammalian metabolic tissues during some conditions only, for example, food deprivation, calorie restriction, or even cold exposure. These conditions have already be linked to a long life. It thus seems that pathways that regulate aging and metabolism converge to some degree, which could lead to a reinvestigation of metabolism in classical models of long-lived animals. The findings presented during the afternoon session obviously raise several questions, among which the search for mutations in Foxo and Sirt1 in humans and their impact on metabolism bears an enormous potential. Also, the effects of these nuclear proteins in modulating the activity of endothelial cells should be determined, in light of the fact that they affect the activity of key regulators such as PPARg in other cell types. In addition, it could be of importance to verify the lifespan of human bearers of PPARg and Foxo mutations. Research on these topics, among several others, should generate ideas and discoveries of potential new targets for the development of therapeutics agents against the metabolic syndrome.
